Skip to content
value.today

Cell Source, Inc. and its peers

1 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.

Companies in the group

Up to 12. Remove or re-base from the table's column heads.

Also: these companies in the compare tool.

Keep this group

Save it for yourself or, in a team, for everyone in it.

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Zivo Bioscience Inc.ZIVO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Karyopharm Therapeutics Inc.KPTI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $146 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Seres Therapeutics, Inc.MCRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Black Hawk Acquisition CorporationBKHA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $20 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Aytu BioscienceAYTU · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (Oct 26, 2026) · revenue $58 M (year to June 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Reviva Pharmaceuticals Holdings, Inc.RVPH · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $21 M (last known, Mar 8, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Sigyn Therapeutics, Inc.SIGY · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (last known, Jan 7, 2022)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Cocrystal Pharma, Inc.COCP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Senti Biosciences, Inc.SNTI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $19 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • BeyondSpring Inc.BYSI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Context Therapeutics Inc.CNTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $22 M (Oct 27, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Lipocine Inc.LPCN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $18 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $18 M (Oct 13, 2026) · revenue $2 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Cell Source, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Cell Source, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCell Source, Inc.base
CLCS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$20 Mlast known, Dec 25, 2022 · Market dataLast known value: no current oneonly one with it$20 M—
Net income (Higher is better)$-5 MFY2024 · SEConly one with it$-5 M—
Scorecard
Scorecard (Higher is better)0 of 6FY2024 · Scorecardonly one with it0% passed—
Growth checks (Higher is better)0 of 2FY2024 · Scorecardonly one with it0% passed—
Profitability checks (Higher is better)0 of 2FY2024 · Scorecardonly one with it0% passed—
Financial health checks (Higher is better)0 of 1FY2024 · Scorecardonly one with it0% passed—
Shareholder returns checks (Higher is better)0 of 1FY2024 · Scorecardonly one with it0% passed—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cell Source, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

Fewer than two years of revenue are on file for these companies.

Rank in the group

Ranks need two fiscal years with the figure for at least two of these companies.